SMARCB1 [3E10] Monoclonal Antibody
- Known as:
- SMARCB1 [3E10] Monoclonal Antibody
- Catalog number:
- 51-916
- Product Quantity:
- 0.05 mg
- Category:
- -
- Supplier:
- Prosci
- Gene target:
- SMARCB1 [3E10] Monoclonal Antibody
Related genes to: SMARCB1 [3E10] Monoclonal Antibody
- Gene:
- SMARCB1 NIH gene
- Name:
- SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1
- Previous symbol:
- SNF5L1
- Synonyms:
- BAF47, Ini1, Snr1, hSNFS, Sfh1p, RDT, PPP1R144, SNF5
- Chromosome:
- 22q11.23
- Locus Type:
- gene with protein product
- Date approved:
- 1995-08-21
- Date modifiied:
- 2019-04-23
Related products to: SMARCB1 [3E10] Monoclonal Antibody
Related articles to: SMARCB1 [3E10] Monoclonal Antibody
- Desmoplastic myxoid tumor of the pineal region, SMARCB1-mutant (DMT-SMARCB1) is a rare central nervous system neoplasm, with only approximately 15 reported cases. Published cases suggest a relatively indolent clinical course with low proliferative activity and no radiologically documented disseminated disease. We report a 47-year-old woman with a pineal region mass who developed aggressive recurrence and focal leptomeningeal dissemination following ventriculoperitoneal shunt placement and Gamma Knife radiosurgery. Histologically, the tumor was composed of discohesive rhabdoid cells embedded within a prominent myxoid stroma and focal collagenous matrix. Immunohistochemistry demonstrated loss of INI1 expression. DNA methylation profiling, interpreted in conjunction with histopathological and immunohistochemical findings, supported the diagnosis of DMT-SMARCB1 and demonstrated molecular proximity to other SMARCB1-deficient central nervous system neoplasms. Literature review revealed no previous reports of radiologically documented leptomeningeal dissemination. This case expands the clinicopathologic spectrum of DMT-SMARCB1 and highlights the potential for aggressive biological behavior despite relatively low-grade histologic features. - Source: PubMed
Publication date: 2026/07/17
Chang Yu-WeiLi Yao-FengChen Yun-AnWang Ren-ChingChang Nien-YiLiao Che-Chi - - Source: PubMed
Publication date: 2026/07/06
Tauziède-Espariat ArnaultDuchesne MathildeRouchaud AymericNegrier Amandine ChabernaudCoudert RomainBenzakoun JosephGuyon DavidSassi FarahHasty LaurenMétais AliceVarlet Pascale - Current World Health Organization (WHO) Classification of Urinary and Male Genital Tumours (2022) has introduced minor updates in the classification of renal cell carcinomas (RCC). Among the most notable changes is the recognition of a new category: molecularly defined RCC. This group comprises several distinct tumour entities characterized by specific genetic alterations. The inclusion of this category reflects the growing importance of molecular testing in the diagnosis, prognosis and treatment planning of renal malignancies. This review summarizes the basic information, clinical data, and treatment options of these rare RCCs. Due to the low prevalence of molecularly defined RCCs, the clinical management remains challenging, and standardized, evidence-based treatment guidelines are still lacking, particularly for the systemic therapy of advanced RCCs. As part of the review, a clinical case of a female patient with metastatic -translocated RCC is also presented, illustrating the diagnostic and therapeutic challenges. - Source: PubMed
Publication date: 2026/07/01
Stránský PetrKolář JiříŠiková DominikaPitra TomášPernický JanFiala OndřejPivovarčíková KristýnaOndič OndrejHora Milan - Epithelioid sarcoma is an exceedingly rare malignant soft tissue neoplasm with unclear histogenesis and distinctive epithelioid morphology. Primary epithelioid sarcoma of orbit represents an extremely rare clinical entity, with only isolated case reports documented globally. Notably, no formal, peer-reviewed case report of primary epithelioid sarcoma of orbit has been published in Asia to date. - Source: PubMed
Publication date: 2026/06/26
Yang GuangYuan JingpingChen FangfangYan HonglinLiu Wen - Schwannomatosis (SWN) is a rare tumor predisposition syndrome caused by pathogenic variants in NF2, SMARCB1, or LZTR1. Mosaicism contributes to up to 30% of de novo NF2-related cases, but its role in SMARCB1- and LZTR1-related SWN remains unclear. Accurate molecular classification is critical for clinical management, yet overlapping phenotypes complicate diagnosis. Because standard diagnostics have limited sensitivity and often require tumor tissue, we evaluated whether ultra-sensitive duplex sequencing of blood-derived DNA improves mosaic variant detection in SWN. - Source: PubMed
Publication date: 2026/07/10
Horbacz MonikaProkopiuk JustynaCastellanos ElisabethBrems HildeBlanco IgnacioLegius EricVan der Auweraer SeppeMoukbel Ali Aldawla ShehabYasari AtenaHeinzl MonikaMadanecki PiotrFilipowicz NataliaGintowt-Chakour AleksandraLipska-Ziętkiewicz Beata SDumanski Jan PTiemann-Boege IrenePiotrowski ArkadiuszKoczkowska Magdalena